Compare AbCellera Biologics Inc (ABCL) vs SoundHound AI Inc (SOUN) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

SoundHound AI (SOUN) trades at $6.96, up 6.26% on the day, with a bearish technical signal despite recent positive earnings beats. The company shows strong revenue growth in auto and IoT AI segments, up 88% year-over-year in Q1 2026, but faces profitability challenges with a net income margin of -91.84% and negative cash flow from operations. Analyst sentiment remains bullish with a $13.00 consensus price target, though the stock is down 37% year-to-date amid concerns over the LivePerson acquisition and high valuation multiples.

The outlook hinges on SOUN's ability to achieve profitability through scaling and cost synergies from acquisitions. Investment opportunities include market expansion in telecom and energy sectors, while risks involve persistent cash burn, competitive pressures, and execution risks in integrating LivePerson. The stock's high short interest could lead to volatility, but analyst optimism suggests potential upside if operational improvements materialize.